Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Company Overview - Nuvation Bio is entering an exciting phase as a commercial-stage company following the acquisition of AnHeart Therapeutics over a year ago, which brought two promising assets [2]. Product Launch and Performance - The first asset, taletrectinib, was approved on June 11 under the brand name IBTROZI, and in its first full quarter, it achieved 204 new patient starts for non-small cell lung cancer, significantly outperforming the previous-generation ROS1 inhibitor, repotrectinib, by approximately six times [3]. - The company reported a nearly 90% response rate for taletrectinib, indicating strong efficacy and potential in the market [4].